APC anti-mouse CD25 Antibody

Product Details

Verified Reactivity

Mouse

Antibody Type

Monoclonal

Host Species

Rat

Immunogen

IL-2-dependent cytolytic mouse T-cell clone B6.1

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.

Concentration

0.2 mg/ml

Storage & Handling

The CD25 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤ 0.25 µg per 10⁶ cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser

Red Laser (633 nm)

Application Notes

Additional reported applications (for the relevant formats) include: immunoprecipitation^1,2, in vitro blocking of IL-2 binding to low- and high-affinity receptors^1-4, growth inhibition of IL-2-dependent T-cell lines^1-4, in vivo depletion of CD25⁺CD4⁺ Treg cells^5-8,10, and immunohistochemical staining of acetone-fixed frozen sections². PC61 antibody recognizes a different epitope than 3C7 antibody (Cat. No. 101902). For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 102040) with endotoxin < 0.01 EU/µg, Azide-Free, 0.2 µm filtered. 

Application References

(PubMed link indicates BioLegend citation)

1. Lowenthal JW, et al. 1985. Nature 315:669. (IP, Block)
2. Ceredig R, et al. 1985. Nature 314:98. (IP, IHC, Block)
3. Lowenthal JW, et al. 1985. J. Immunol. 135:3988. (Block)
4. Moreau JL, et al. 1987. Eur. J. Immunol. 17:929. (Block)
5. Takahashi T, et al. 2000. J. Exp. Med. 192:303. (Deplete)
6. Onizuka S, et al. 1999. Cancer Res. 59:3128. (Deplete)
7. Lei TC, et al. 2005. Blood 105:4865. (Deplete)
8. Pasare C, et al. 2004. Immunity 21:733. (Deplete)
9. León-Ponte M, et al. 2007. Blood 109:3139.
10. Cao OW, et al. 2007. Blood doi:10.1182/blood-2007-02-073304. (Deplete)
11. Benson MJ, et al. 2007. J. Exp. Med. doi:10.1084/jem.20070719.
12. Liu F, et al. 2011. Arch Toxicol. 85:1383. PubMed
13. Anguela XM, et al. 2013. Diabetes. 62:551. PubMed

Product Citations

1. Schuster M, et al. 2017. J Immunol. 199:920. PubMed
2. Deák P, et al. 2022. Cell Rep. 41:111563. PubMed
3. Sohn HS, et al. 2022. Sci Adv. 8:eabo5284. PubMed
4. Lee AR, et al. 2023. Cell Commun Signal. 21:44. PubMed
5. Wang JX, et al. 2023. JCI Insight. 8:. PubMed
6. Tan X, et al. 2023. Adv Sci (Weinh). 10:e2206768. PubMed
7. Zhou X, et al. 2023. Sci Rep. 13:6701. PubMed
8. Tian J, et al. 2021. Autophagy. 17:2586. PubMed
9. Russler-Germain EV, et al. 2021. Immunity. 54:2547. PubMed
10. Chaurio RA, et al. 2022. Immunity. 55:115. PubMed
11. Saxena V, et al. 2022. Cell Rep. 39:110727. PubMed
12. Que W, et al. 2022. Sci Adv. 8:eabo4413. PubMed
13. Zhu J, et al. 2022. Nat Commun. 13:7466. PubMed
14. Liu P, et al. 2023. Clin Immunol. 246:109212. PubMed
15. Jin SM, et al. 2023. Nat Nanotechnol. :. PubMed
16. Pinto NA, et al. 2023. Cell Death Differ. :. PubMed
17. Reticker-Flynn NE, et al. 2022. Cell. 185:1924. PubMed
18. Shi L, et al. 2019. Theranostics. 9:4115. PubMed
19. Lyons J, et al. 2018. PLoS Biol. 16:e2002417. PubMed
20. Prajeeth C,et al. 2017. J Neuroinflammation.. 10.1186/s12974-017-0978-3. PubMed
21. Shibata K, et al. 2022. Nat Commun. 13:6948. PubMed
22. Otano I, et al. 2021. Nat Commun. 12:7296. PubMed
23. Koh CH, et al. 2020. Cancer Immunol Res. 8:698. PubMed
24. Noris M, et al. 2009. J Immunol. 183:4249. PubMed
25. Kolbus D, et al. 2011. Immunobiology. 216:663. PubMed
26. Gravano D, et al. 2010. PLoS One. 5:e13528. PubMed
27. Annu K, et al. 2020. Sci Rep. 10:2359. PubMed
28. Cheng G, et al. 2021. iScience. 24:102673. PubMed
29. Delacher M, et al. 2021. Immunity. 54(4):702-720.e17. PubMed
30. Waysbort N, et al. 2013. J Immunol. 191:5822. PubMed
31. Hayatsu N et al. 2017. Immunity. 47(2):268-283 . PubMed
32. Kang TH, et al. 2019. Tissue Eng Regen Med. 16:539. PubMed
33. Sugimoto C, et al. 2022. Elife. 11:. PubMed
34. Shi L, et al. 2021. Immunity. . PubMed
35. Stahlhut M, et al. 2021. Sci Rep. 11:5294. PubMed
36. Zimmermann J, et al. 2017. Eur J Immunol. 10.1002/eji.201747100. PubMed
37. Horikoshi M, et al. 2012. PLoS One. 7:e51215. PubMed
38. Min H, et al. 2015. PLoS One. 10: 0138201. PubMed
39. Jassinskaja M, et al. 2021. Cell Reports. 34(12):108894. PubMed
40. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
41. Zhang B, et al. 2021. Nat Biomed Eng. 5:1288. PubMed
42. Park D, et al. 2020. Cancer Res. 80:4172. PubMed
43. Rengarajan S, et al. 2020. Cell Rep Med. :1. PubMed
44. Yue X, et al. 2019. Nat Commun. 10:2011. PubMed
45. Wang SS, et al. 2021. Biomedicines. 9:. PubMed
46. Russler-Germain EV, et al. 2021. Elife. 10:. PubMed
47. Zhong W, et al. 2022. Nat Commun. 13:4390. PubMed
48. Chin AL, et al. 2021. Nat Commun. 12:5138. PubMed
49. Jing Y, et al. 2020. Sci Adv. 6:eaax9455. PubMed
50. Kim JH, et al. 2019. Mol Med. 25:33. PubMed
51. Bergin SM, et al. 2021. Brain Behav Immun. 95:477. PubMed
52. Zeng Q, et al. 2022. Front Immunol. 13:740805. PubMed
53. Volberding PJ, et al. 2021. Cell Reports. 35(8):109160. PubMed
54. Glassman CR, et al. 2021. eLife. 10:00. PubMed
55. Dou G, et al. 2020. Sci Adv. 6:eaba2987. PubMed
56. Pierini A, et al. 2017. JCI Insight. 2. PubMed
57. Kemp V, et al. 2018. Cancer Gene Ther. 26:268. PubMed
58. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
59. Webb ER, et al. 2022. iScience. 25:104995. PubMed
60. Wigren M, et al. 2011. J Intern Med. 269:546. PubMed
61. Vaena S, et al. 2021. Cell Reports. 35(5):109076. PubMed
62. Liu X, et al. 2021. Int J Nanomedicine. 16:5675. PubMed
63. Frost JN, et al. 2021. Med (N Y). 2:164. PubMed
64. Glassman CR, et al. 2021. Cell. 184(4):983-999.e24. PubMed
65. Oomizu S, et al. 2012. Clin Immunol. 143:51. PubMed
66. Kolev M, et al. 2020. Immunity. 52(3):513-527. PubMed
67. Aftabizadeh M, et al. 2021. JCI Insight. 6:. PubMed
68. Xu Q, et al. 2021. Theranostics. 11:1937. PubMed
69. Kang CK, et al. 2021. J Infect Dis. 224:39. PubMed
70. Tu J, et al. 2022. Mol Ther Nucleic Acids. 27:733. PubMed
71. Wei Z, et al. 2021. Nat Commun. 0.805555556. PubMed
72. Baomei Wang et al. 2019. Cell reports. 26(6):1614-1626 . PubMed
73. Nenasheva T, et al. 2017. PLoS One. 12(6):e0178983. PubMed
74. Matsumura T, et al. 2022. Nat Commun. 13:7064. PubMed
75. Ahn SH, et al. 2022. Front Endocrinol (Lausanne). 13:846226. PubMed
76. Martomo SA, et al. 2021. Mol Cancer Ther. 1.074305556. PubMed
77. Long C, et al. 2016. Toxicol Sci. 152: 85 - 98. PubMed
78. Pardo E, et al. 2017. PLoS One. 12(6):e0177472. PubMed
79. Wang T et al. 2018. Immunity. 49(3):504-514 . PubMed
80. Barbet G, et al. 2018. Immunity. 48:584. PubMed
81. Chen X, et al. 2019. Med Sci Monit. 25:5389. PubMed
82. Yue X, et al. 2021. EMBO Rep. 22:e52716. PubMed
83. O'Donoghue GP, et al. 2021. Proc Natl Acad Sci U S A. 118:. PubMed
84. Tsai HI, et al. 2021. EMBO Mol Med. 13:e12834. PubMed
85. Hoover AR, et al. 2022. Clin Transl Med. 12:e937. PubMed
86. Kobia FM, et al. 2020. PLoS Biol. 18:e3000850. PubMed
87. Chen C, et al. 2020. Front Cell Neurosci. 14:8. PubMed
88. Niven J, et al. 2019. Cell Rep. 28:21. PubMed
89. Schuster M, et al. 2019. Front Immunol. 10:1583. PubMed
90. Alenazy MF, et al. 2022. PLoS One. 17:e0271689. PubMed
91. Shaikh H, et al. 2021. Front Immunol. 12:689896. PubMed
92. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
93. Tanaka S, et al. 2016. Appl Envir Microbiol. 82: 2693 - 2699. PubMed
94. Chao JL, et al. 2021. Cell Rep Med. 2:100399. PubMed
95. Tassi I, et al. 2014. J Immunol. 193:4303. PubMed
96. Wong E, et al. 2015. J Immunol. 194:4130. PubMed
97. Yang X, et al. 2021. Bioact Mater. 3150:6. PubMed
98. Sun Y, et al. 2022. iScience. 25:104846. PubMed
99. Schulze J, et al. 2021. Stroke. 52:2939. PubMed
100. Kashiwakura Y, et al. 2020. Clinical & Experimental Immunology. 202(1):119-135. PubMed
101. Deptuch T, et al. 2022. Sci Rep. 12:13480. PubMed
102. Katsuyama T, et al. 2021. Cell Reports. 36(1):109339. PubMed
103. Angelou CC, et al. 2020. Frontiers in Immunology. 2.586805556. PubMed
104. Johnson JL et al. 2018. Immunity. 48(2):243-257 . PubMed
105. Li CY, et al. 2022. Int J Mol Sci. 23:. PubMed
106. Erens C, et al. 2022. Biomedicines. 10:. PubMed
107. Hester AK, et al. 2022. Cell Rep. 38:110363. PubMed
108. Park JS, et al. 2022. J Transl Med. 20:85. PubMed
109. Rana MN, et al. 2021. Front Pharmacol. 12:643215. PubMed
110. Du Z, et al. 2020. J Allergy Clin Immunol. . PubMed
111. Ye Y, et al. 2020. Genome Med. 0.557638889. PubMed

RRID

AB_312860 (BioLegend Cat. No. 102011)
AB_312860 (BioLegend Cat. No. 102012)

Antigen Details

Structure

Forms high affinity IL-2R with IL-2Rβ (CD122) and IL-2Rγ (CD132), 55 kD

Distribution

Activated T cells and B cells, thymocyte subset, pre-B cells, T regulatory cells

Function

IL-2 receptor

Ligand/Receptor

IL-2

Cell Type

B cells, T cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules, Cytokine/Chemokine Receptors

Antigen References

1. Taniguchi T, et al. 1993. Cell 73:5-8.
2. Waldmann TA. 1991. J Biol Chem. 266:2681-4.
3. Read S, et al. 2000. J Exp Med. 192:295-302.
4. Lowenthal JW, et al. 1985. J Immunol. 135:3988-94.

Gene ID

16184 View all products for this Gene ID

UniProt

View information about CD25 on UniProt.org

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Other Formats